Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access
Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc
Journal website

Original Article

Volume 12, Number 5, October 2021, pages 309-317

An Analysis of Global Research Trends and Top-Cited Research Articles in Cardio-Oncology


Figure 1.
Figure 1. Trends of global cardio-oncology research. Results from bibliometric analysis from 1864 to 2020 illustrate number of publications (a) and number of citations of articles (b) in cardio-oncology.


Table 1. Fifty Top Cited Articles in Cardio-Oncologya
CitationsYearJournalAuthorsCorresponding author (Country)TitleDocument typeCorresponding author field
aData as of final search date March 31, 2021. bPP or Guide: position paper or guideline.
19862016European Heart JournalZamorano JL et alZamorano JL (Spain)2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesPP or GuidebCardiology
24992010Journal of the National Cancer InstituteAlbini A et alAlbini A (Italy)Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological preventionReviewMolecular oncology
34632012Annals of OncologyCurigliano G et alCurigliano G (Italy)Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelinesPP or GuideOncology
43212018Journal of the American College of CardiologyMahmood SS et alNeilan TG (USA)Myocarditis in Patients Treated with Immune Checkpoint InhibitorsOriginal articleCardiology
52882011European Journal of Heart FailureEschenhagen T et alEschenhagen T (Germany)Cardiovascular side effects of cancer therapies: A position statement from the Heart Failure Association of the European Society of CardiologyPP or GuideCardiology
62702014Journal of the American College of CardiologyKy B et alKy B (USA)Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumabOriginal articleCardiology
72562013European Heart JournalSuter TM et alSuter TM (Switzerland)Cancer drugs and the heart: Importance and managementReviewCardiology
82182017Canadian Journal of CardiologyEzekowitz JA et alEzekowitz JA (Canada)2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart FailurePP or GuideCardiology
92032012Journal of the American College of CardiologyChen J et alChen J (USA)Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast CancerOriginal articleCardiology
101992013JACC: Cardiovascular ImagingDrafts BC et alHundley WG (USA)Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular diseaseOriginal articleCardiology
111842016CA: A Cancer Journal for CliniciansCurigliano G et alCurigliano G (Italy)Cardiotoxicity of Anticancer Treatments: Epidemiology, Detection, and ManagementReviewOncology
121722014Mayo Clinic ProceedingsHerrmann J et alHerrmann J (USA)Evaluation and management of patients with heart disease and cancer: Cardio-oncologyReviewCardiology
131642017Journal of the American College of CardiologyCollier P et alCollier P (USA)A Test in Context: Myocardial Strain Measured by Speckle-Tracking EchocardiographyReviewCardiology
141462014Journal of the American Heart AssociationHahn VS et alLenihan DJ (USA)Cancer therapy-induced cardiotoxicity: Basic mechanisms and potential cardioprotective therapiesReviewCardiology
151432017Journal of Clinical OncologyPituskin E et alPaterson DI (Canada)Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): A randomized trial for the prevention of trastuzumab-associated cardiotoxicityOriginal articleCardiology
161402014Journal of the American College of CardiologyFarmakis D et alFilippatos G (Greece)Insights Into Onco-Cardiology Atrial Fibrillation in CancerReviewCardiology
171262016Circulation ResearchLenneman CG et alLenneman CG (USA)Cardio-Oncology An Update on Cardiotoxicity of Cancer-Related TreatmentReviewCardiology
181182015Plos OneFocaccetti C et alAlbini A (Italy)Effects of 5-Fluorouracil on Morphology, Cell Cycle, Proliferation, Apoptosis, Autophagy and ROS Production in Endothelial Cells and CardiomyocytesOriginal articleMolecular oncology
191112015Journal of the American College of CardiologyBarac A et alBarac A (USA)Cardiovascular health of patients with cancer and cancer survivors: A roadmap to the next levelReviewCardiology
201102012Experimental and Molecular PathologyWeerasinghe, P et alWeerasinghe P (USA)Oncosis: An important non-apoptotic mode of cell deathReviewPathology
211082013Drug SafetyShah RR et alShah RR (UK)Cardiovascular safety of tyrosine kinase inhibitors: With a special focus on cardiac repolarisation (QT Interval)ReviewCardiology
221042013Circulation ResearchKy B et alMoslehi J (USA)Emerging paradigms in cardiomyopathies associated with cancer therapiesReviewCardiology
23922017OncotargetKoleini N et alKardami E (Canada)Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicityReviewMolecular biology
24912016Canadian Journal of CardiologyVirani SA et alVirani SA (Canada)Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer TherapyPP or GuideCardiology
25892015Journal of the American College of CardiologyLi W et alMoslehi J (USA)Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase InhibitorsReviewCardiology
26822014Journal of Pineal ResearchGovender J et alEngelbrecth, A (South Africa)Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: A review of the protective role of melatoninReviewPhysiology
27792019Cardiovascular ResearchHu JR et alMosheli J (USA)Cardiovascular toxicities associated with immune checkpoint inhibitorsReviewCardiology
28732017Lancet OncologyLevis BE et alShapiro CL (USA)Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?ReviewOncology
29732020Annals of OncologyCurigliano G et alESMO Guidelines CommitteeManagement of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendationsPP or GuideOncology
30692019European Heart JournalLancellotti P et alLancelloti P (Belgium)Cardio-oncology services: Rationale, organization, and implementatio: A report from the ESC Cardio-Oncology councilReviewCardiology
31692018European Journal of CancerCardinale D et alLatini R (Italy)Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trialOriginal articleCardiology
32682017Journal for Immunotherapy of CancerNorwood TG et alConry RM (USA)Smoldering myocarditis following immune checkpoint blockadeCase ReportOncology
33682016Catheterization and Cardiovascular InterventionsIliescu CA et alMarmagkiolis K (USA)SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologa intervencionista)PP or GuideCardiology
34682015CirculationBellinger AM et alMoslehi J (USA)Cardio-oncology: How new targeted cancer therapies and precision medicine can inform cardiovascular discoveryReviewCardiology
35672016Mayo Clinic ProceedingsAl-Kindi SG et alOliveira GH (USA)Prevalence of Preexisting Cardiovascular Disease in Patients with Different Types of Cancer the Unmet Need for Onco-CardiologyOriginal articleCardiology
36662010Journal of Pharmacology and Experimental TherapeuticsMinotti G et alMinotti G (Italy)Pharmacological foundations of cardio-oncologyReviewPharmacology
37652013Journal of Nuclear CardiologySchwartz RG et alStorozynsky E (USA)Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasivelyReviewCardiology
38642018Pharmacological ResearchCappetta D et alDe Angelis A (Italy)Doxorubicin targets multiple players: A new view of an old problemReviewCardiology
39632019CirculationBonaca MP et alBonaca MP (USA) Moslehi J (USA)Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-OncologyReviewCardiology
40612019European Heart JournalSturgeon KM et alZaorsky NG (USA)A population-based study of cardiovascular disease mortality risk in US cancer patientsOriginal articleRadiation oncology
41602017Revista Espanola de CardiologiaLopez-Fernandez T et alLopez-Fernandez T (Spain)Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations (Cardio-Onco-Hematologia en la practica clinica. Documento de consenso y recomendaciones)PP or GuideCardiology
42592010Clinical CardiologyHong RA et alLimura T (USA)Cardio-oncology/onco-cardiologyReviewInternal medicine
43592016World Journal of CardiologyCuomo JR et alWeintraub NL (USA)Novel concepts in radiation-induced cardiovascular diseaseReviewCardiology
44582018CirculationScott, JM et alScott JM (USA)Exercise Therapy and Cardiovascular Toxicity in CancerReviewExercise oncology
45582014International Journal of CardiologyPatane SPatane S (Italy)Cardiotoxicity: Cisplatin and long-term cancer survivorsLetter to EditorCardiology
46582018Basic Research in CardiologyDavidson SM et alYellon DM (UK)The 10th Biennial Hatter Cardiovascular Institute workshop: cellular protection - evaluating new directions in the setting of myocardial infarction, ischaemic stroke, and cardio-oncologyMeeting ReportMolecular and cellular cardiology
47532016Canadian Journal of CardiologyJohnson CB et alJohnson CB (Canada)Shared Risk Factors for Cardiovascular Disease and Cancer: Implications for Preventive Health and Clinical Care in Oncology PatientsReviewCardiology
48522019CirculationGilchrist SC et alAmerican Heart Association (USA)Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement from the American Heart AssociationPP or GuideCardiology
49502017Journal of the American Heart AssociationPorta-Sanchez A et alThavendiranathan P (Canada)Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: A systematic reviewSystematic reviewCardiology
50492013Journal of the American College of CardiologyLal H et alForce T (USA)Cancer Genetics and the Cardiotoxicity of the TherapeuticsReviewCardiology


Table 2. Top 10 Journals for Cardio-Oncology Publicationsa
Journal titleNumber of published articles
aData as of final search date March 31, 2021.
JACC: Cardiooncology51
International Journal of Cardiology40
Journal of the American College of Cardiology40
European Journal of Heart Failure36
Current Treatment Options in Cardiovascular Medicine30
European Heart Journal23
Journal of the American Heart Association19
Current Cardiology Reports18